Sign in

CIK 0001658551

  • Non-accelerated filer
  • Smaller reporting company

Amylyx Pharmaceuticals, Inc.

Sign in to watch
Ticker
AMLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464600503
Phone
+1 617-682-0917
Business address
55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
  1. 4 Open-market sale 10% owner sold 100,000 shares at an average $35.78 ($3,578,103)
  2. 5 Insider Annual Insider Trading Report
  3. 5 Insider Annual Insider Trading Report
  4. 4 Open-market sale Chief Medical Officer sold 2,034 shares at an average $36.30 ($73,831)
  5. 4 Open-market sale Co-Chief Executive Officer sold 5,968 shares at an average $36.30 ($216,629)
  6. 4 Open-market sale Chief Financial Officer sold 2,658 shares at an average $36.30 ($96,481)
  7. 4 Open-market sale Chief Commercial Officer sold 2,403 shares at an average $36.30 ($87,225)
  8. 4 Open-market sale Co-Chief Executive Officer sold 5,968 shares at an average $36.30 ($216,629)
  9. 4 Option exercise Chief Financial Officer acquired 5,000 shares (option exercise)
  10. 4 Open-market sale 10% owner sold 1,400,000 shares at an average $29.80 ($41,719,639)
  11. 4 Open-market sale 10% owner sold 60,609 shares at an average $20.70 ($1,254,642)
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Option exercise Co-Chief Executive Officer acquired 334,520 shares (option exercise)
  17. 4 Option exercise Co-Chief Executive Officer acquired 334,520 shares (option exercise)
  18. 4 Conversion 10% owner acquired 5,955,889 shares (conversion)
  19. 3 Insider Initial Statement of Ownership
  20. 4 Derivatives Options or other derivatives

Page 9 of 11 · 207 filings